Baidu
map

J Clin Oncol:维奈托克联合吉特替尼治疗FLT3突变型急性髓系白血病

2022-08-01 MedSci原创 MedSci原创

维奈托克联合吉特替尼治疗FLT3mut 急性髓系白血病可获得较高的mCRc和FLT3分子反应率

FMS相关酪氨酸激酶3(FLT3)抑制剂吉特替尼(gilteritinib)是复发性/难治性FLT3突变型(FLT3mut)急性髓系白血病(AML)的标准疗法,但其很少能降低患者的FLT3mut负担或诱导持续疗效。在FLT3mut AML的临床前模型中,吉特替尼与BCL-2抑制剂维奈托克具有协同作用。

本研究是一项开放标签的剂量递增/剂量扩展性Ib期研究,招募了FLT3野生型和FLT3mut(剂量递增)或FLT3mut(剂量扩展)复发性/难治性AML患者,予以口服维奈托克(400 mg/日)和吉特替尼(80 mg或120 mg/日)治疗。主要终点是安全性、明确推荐的II期剂量、改良的复合完全缓解(mCRc)率(完全缓解率[CR]+CR伴不完全血细胞计数恢复+CR伴不完全血小板恢复+形态学无白血病状态)。


缓解情况

共招募了61位患者(FLT3mut,n=56);64%的FLT3mut 患者既往接受过FLT3抑制剂治疗。推荐的II期剂量是维奈托克 400 mg(1/日)+吉特替尼 120 mg(1/日)。最常见的3/4级不良反应有血细胞减少(n=49;80%)。51%的患者因不良反应中断维奈托克治疗,48%的患者因不良反应中断吉特替尼治疗。


FLT3mut 患者的总生存率

FLT3mut 患者的mCRc率是75%(CR 18%;CR伴不完全血细胞计数恢复 4%;CR伴不完全血小板恢复 18%;形态学无白血病状态 36%),既往有无FLT3抑制剂治疗史的患者之间相似(80% vs 67%)。中位随访了17.5个月。获得缓解前的中位时间是0.9个月,中位缓解持续时间是4.9个月。60%(15/25)的可评估的mCRc患者获得了FLT3分子反应(<10-2)。FLT3mut 患者的中位总生存期是10.0个月。

总之,维奈托克联合吉特替尼治疗FLT3mut 急性髓系白血病可获得较高的mCRc和FLT3分子反应率,无论患者既往是否接受过FLT3抑制剂治疗。

 

原始出处:

Naval Daver, et al. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. J Clin Oncol. July 18, 2022. https://ascopubs.org/doi/full/10.1200/JCO.22.00602

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1866671, encodeId=7e0818666e159, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Aug 07 07:18:00 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041439, encodeId=b989204143993, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Oct 23 07:18:00 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822135, encodeId=90461822135c1, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 22 06:18:00 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538905, encodeId=880815389055c, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7514, encryptionId=5f04e51467, topicName=FLT3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57a713069145, createdName=fengyi816, createdTime=Wed Aug 03 01:18:00 CST 2022, time=2022-08-03, status=1, ipAttribution=)]
    2022-08-07 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1866671, encodeId=7e0818666e159, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Aug 07 07:18:00 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041439, encodeId=b989204143993, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Oct 23 07:18:00 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822135, encodeId=90461822135c1, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 22 06:18:00 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538905, encodeId=880815389055c, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7514, encryptionId=5f04e51467, topicName=FLT3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57a713069145, createdName=fengyi816, createdTime=Wed Aug 03 01:18:00 CST 2022, time=2022-08-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1866671, encodeId=7e0818666e159, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Aug 07 07:18:00 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041439, encodeId=b989204143993, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Oct 23 07:18:00 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822135, encodeId=90461822135c1, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 22 06:18:00 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538905, encodeId=880815389055c, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7514, encryptionId=5f04e51467, topicName=FLT3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57a713069145, createdName=fengyi816, createdTime=Wed Aug 03 01:18:00 CST 2022, time=2022-08-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1866671, encodeId=7e0818666e159, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Aug 07 07:18:00 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041439, encodeId=b989204143993, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Oct 23 07:18:00 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822135, encodeId=90461822135c1, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 22 06:18:00 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538905, encodeId=880815389055c, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7514, encryptionId=5f04e51467, topicName=FLT3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57a713069145, createdName=fengyi816, createdTime=Wed Aug 03 01:18:00 CST 2022, time=2022-08-03, status=1, ipAttribution=)]
    2022-08-03 fengyi816

相关资讯

JCI:CDK1或成为急性髓细胞性白血病治疗新靶标

急性髓细胞性白血病(acute myeloid leukemia, AML, 也译作急性髓系白血病或急性髓性白血病)是成年人身上常见的一种白血病,其特征在于癌性骨髓细胞(cancerous bone marrow cell)异常增殖。在急性髓细胞性白血病中,人们观察到的的最为流行的突变之一就是一种被称作FLT3受体的蛋白受体存在激活突变。FLT3突变体被认为能够激活促进癌症生长的信号途径。 来自

Baidu
map
Baidu
map
Baidu
map